Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
CARDIOLOGY / RESEARCH LETTER
GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular practice: insights from a national survey of French cardiologists
1
Sorbonne University, ACTION Study Group, INSERM UMRS_1166, Cardiology Institute, Pitié Salpêtrière Hospital (AP-HP) Paris, Paris, France
2
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
3
Universidade de São Paulo Faculdade de Medicina: São Paulo, Brazil
4
Department of Cardiology, CMC Ambroise Paré, Neuilly-sur-Seine, France
5
University of Florida: Gainesville, Florida, United States
6
Collège National des Cardiologues Français, Paris, France
7
Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
8
Policlinico Casilino, Italy
9
Department of Clinical and Experimental Medicine, University of Messina, Italy
10
Cardiovascular Research Centre, University of Zielona Gora, Poland
11
Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Henri Mondor University Hospital, Créteil, France
Submission date: 2026-05-27
Final revision date: 2026-07-19
Acceptance date: 2026-07-26
Online publication date: 2026-07-26
Corresponding author
Pierre F. Sabouret
Sorbonne University ACTION Study Group INSERM UMRS_1166 Cardiology Institute Pitié Salpêtrière Hospital (AP-HP) Paris, France
Sorbonne University ACTION Study Group INSERM UMRS_1166 Cardiology Institute Pitié Salpêtrière Hospital (AP-HP) Paris, France
TOPICS
ABSTRACT
Introduction:
Not applicable.
Material and methods:
Not applicable.
Results:
Not applicable.
Conclusions:
Not applicable.
Not applicable.
Material and methods:
Not applicable.
Results:
Not applicable.
Conclusions:
Not applicable.
REFERENCES (13)
1.
Marx N, Federici M, Schutt K, et al.; Group ESCSD. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043-140.
2.
ElSayed NA, Aleppo G, Aroda VR, et al.; the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46: S158-90.
3.
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-86.
4.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140: e596-646.
5.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation 2019; 139: e1082-143.
6.
Bernardi M, Spadafora L, Galli M, Biondi-Zoccai G, Sabouret P. Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients? Arch Med Sci 2023; 19: 528-31.
7.
Eckel RH, Blaha MJ. Cardiometabolic medicine: a call for a new subspeciality training track in internal medicine. Am J Med 2019; 132: 788-90.
8.
Saxon DR, Reiter-Brennan C, Blaha MJ, Eckel RH. Cardiometabolic medicine: development of a new subspecialty. J Clin Endocrinol Metab 2020; 105: dgaa261.
9.
Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 2023; 148: 1606-35.
10.
Katsiki N, Kolovou G, Vrablik M. Metabolic dysfunction associated-steatotic liver disease (MASLD) and cardiovascular risk: embrace all facets of the disease. Curr Cardiol Rep 2025; 27: 19.
11.
Katsiki N, Kolovou G, Melidonis A, Banach M. The cardiac-kidney-liver (CKL) syndrome: the “real entity” of type 2 diabetes mellitus. Arch Med Sci 2024; 20: 207-15.
12.
Muzurović E, Katsiki N, Volčanšek Š, Plescia F, Rizzo M, Mantzoros CS. Emerging incretin- and multi-agonist-based treatments: the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism 2026; 177: 156494.
13.
American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of care in diabetes-2026. Diabetes Care 2026; 49 (Suppl 1): S246-60.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
